Who Chooses the Brand — Used in Your Chemotherapy?
The hospital decides which brand of chemotherapy it stocks and uses — and many patients do not know they can ask about alternatives. In India, CDSCO-approved generics and originator brands of the same molecule must both meet the same regulatory requirements. This page explains how that decision is made and what you can reasonably ask your team.
- The hospital decides — Procurement agreements made at an institutional level determine which brand the pharmacy stocks — not a choice made at your individual consultation.
- The molecule is the same — A CDSCO-approved generic contains the same active ingredient at the same dose as the originator brand of that molecule.
- You can ask — Asking your oncologist whether a generic is available for your treatment is a reasonable question. Most hospitals will engage with it.
- Bringing your own is rarely possible — Chemotherapy must be prepared and administered under controlled hospital conditions. External supply is not standard practice at any centre.
Medically reviewed by Dr. Owais Mohammed, Medical Oncologist · Last reviewed September 2026
The hospital decides which brand of chemotherapy it stocks and administers. That choice is driven by its procurement agreements, not by the molecule. You can ask your oncologist whether a CDSCO-approved generic is available for your treatment — most hospitals will discuss it. Bringing medicine from outside the hospital is rarely practical.
What is the difference between an originator brand and an Indian generic?
| Originator brand | Indian generic (CDSCO-approved) | |
|---|---|---|
| What it is | The product approved under the molecule's original clinical name, made by the company that developed and patented it | A chemically identical product made under a separate manufacturing licence, typically once the molecule is off-patent or licensed |
| Active molecule | The compound that treats the cancer, at the prescribed dose | The same compound at the same dose — CDSCO approval requires this |
| Indian regulatory approval | Required before any hospital can use it in India | Required before any hospital can use it — quality standards apply equally |
| Who sources it | The hospital pharmacy, under its procurement agreement | The hospital pharmacy — a different supplier, the same sourcing process |
| Cost indication | Higher — reflects original research, development, and clinical programme costs | Meaningfully lower in many cases — these development costs do not apply to the generic manufacturer |
| Can you discuss it with your team | Ask your oncologist if this is what the hospital currently stocks | Ask your oncologist whether a generic is available and can be sourced for your treatment |
How does the hospital decide which brand you receive?
The hospital's pharmacy stocks specific products based on procurement agreements negotiated in advance — usually at volume, across many patients and treatment cycles. Your oncologist works from what the pharmacy supplies.
These agreements reflect regulatory approval, available supply, logistics, and negotiated pricing. The decision happens at an institutional level, before your individual consultation.
This is standard practice in Indian oncology. It does not change the regulatory requirements any product must meet. CDSCO approval is a condition of use regardless of which brand is on the shelf.
Who should not receive chemotherapy?
Chemotherapy is not appropriate for everyone. Eligibility is decided by an oncologist on the individual case, based on your diagnosis, organ function, blood counts, and overall health.
Groups for whom chemotherapy is typically not used, or used only with careful modification:
- People with severely impaired kidney or liver function that would prevent the drug from being cleared safely.
- People with dangerously low blood cell counts that have not been corrected before treatment begins.
- People with active, uncontrolled infection.
- People in very poor general health who are unlikely to tolerate the side effects of treatment.
- People who have already received the maximum safe cumulative dose of a particular agent.
- Pregnant women, for most chemotherapy agents, particularly in the first trimester.
This list is not exhaustive. Your oncologist reviews your full clinical picture before recommending any treatment.
What does 'generic' actually mean for a chemotherapy drug?
- Originator brand
- The product that was first developed and approved when the molecule was new. It carries the original trade name and was made by the company that ran the clinical trials and held the patent.
- Generic (small molecule)
- A product containing the same active chemical molecule, at the same dose, approved by the regulator once the originator's patent or market exclusivity has ended. It is manufactured under the same quality standards required of all approved products.
- Biosimilar
- The biological equivalent of a generic, but for large, complex molecules made by living cells — such as monoclonal antibodies used in targeted therapy. These cannot be identically copied the way a small chemical molecule can. CDSCO applies a more demanding comparability assessment before approving a biosimilar.
- CDSCO
- The Central Drugs Standard Control Organisation — India's national drug regulator. No medicine can legally be manufactured, imported, or used in India without CDSCO approval. Both originator brands and generics must meet its standards.
- Procurement formulary
- The list of products a hospital has approved for use, based on its supply agreements. What appears on the formulary is what the pharmacy stocks. This is what your treatment team will use unless a specific exception is arranged.
Can you ask for a different brand, or bring your own medicine?
You can ask. Raise it with your oncologist, not directly with the pharmacy. Ask whether a CDSCO-approved generic is available for your specific molecule and whether the hospital can source it through its procurement process.
Many hospitals will accommodate this, particularly where the generic is widely available and the clinical protocol does not specify a brand by name. Hospitals that treat high volumes of patients often have more sourcing flexibility.
Bringing chemotherapy from outside — from another pharmacy, another city, or abroad — is not standard practice at any Indian oncology centre. Chemotherapy requires specialist preparation under controlled conditions. Hospitals carry regulatory responsibility for every product they administer and will not accept medicine sourced externally.
Explore 74 more Chemotherapy and Supportive Medicines by Name topics
Generic, Branded & Biosimilar Chemotherapy in India
- Amrit Pharmacy and Subsidised Cancer Drugs
- Biosimilars: Quality, Regulation and Price
- Can You Buy Chemotherapy Drugs Yourself?
- Cold Chain and Drug Storage: Why It Matters
- Counterfeit and Substandard Cancer Drugs
- Generic vs Branded Chemotherapy in India
- How to Check a Chemotherapy Drug Is Approved
- Is Generic Chemotherapy Safe?
- Jan Aushadhi and Government Pharmacy Options
- Patient Assistance Programmes for Cancer Drugs
- Price Control on Cancer Drugs in India
- Questions to Ask About the Drugs You Are Given
- Rituximab Biosimilars in India
- Trastuzumab Biosimilars in India
- Who Chooses the Brand Used for Your Treatment?
- Why the Same Drug Costs Ten Times More
Chemotherapy Drugs by Name
- 5-Fluorouracil (5-FU, Fluracil): What to Expect
- Bleomycin (Bleocip): What to Expect
- Capecitabine (Xeloda, Capegard, Xabine): The Tablet Form
- Carboplatin (Carboplat, Kemocarb): What to Expect
- Chemotherapy Drug Classes Explained
- Chemotherapy Drug Cost by Name
- Chemotherapy Drugs: A Complete Guide by Name
- Cisplatin (Cisplan, Kemoplat): What to Expect
- Cyclophosphamide (Endoxan, Cycloxan): What to Expect
- Cytarabine (Cytosar): What to Expect
- Docetaxel (Taxotere, Docetax, Daxotel): What to Expect
- Doxorubicin (Adrim, Adriamycin): The Red Injection
- Epirubicin: What to Expect
- Etoposide (Etosid, Fytosid): What to Expect
- Gemcitabine (Gemcite, Gemtaz, Oncogem): What to Expect
- Ifosfamide (Holoxan) and Mesna: Why They Go Together
- Irinotecan (Irinotel): What to Expect
- Liposomal Doxorubicin (Lipodox, Caelyx): How It Differs
- Methotrexate (Folitrax): What to Expect
- Mitomycin, Actinomycin and Less Common Agents
- Nab-Paclitaxel (Abraxane, Nabtaxel): How It Differs
- Oxaliplatin (Oxaliplat, Dacotin): What to Expect
- Paclitaxel (Paclitax, Intaxel, Oncotaxel): What to Expect
- Pemetrexed (Alimta, Pemgem, Pemnat): What to Expect
- Reading Your Chemotherapy Chart
- Temozolomide (Temodal, Temoget): The Brain Tumour Tablet
- Vincristine (Cytocristin, Oncovin): What to Expect
- Vinorelbine (Navelbine): What to Expect
- Which Drugs Affect Fertility?
- Which Drugs Affect the Heart, Kidneys or Lungs?
- Which Drugs Cause Hair Loss and Which Do Not?
- Which Drugs Cause Nausea and How Much?
- Which Drugs Cause Neuropathy?
- Why Was This Particular Drug Chosen for Me?
Drug Interactions, TB & Chronic Medicines
HUB — Chemotherapy Drugs by Name
HUB — Generic, Branded and Biosimilar Chemotherapy in India
HUB — Supportive Medicines Used With Chemotherapy
Supportive Medicines by Name
- Acid Blockers (Pantocid, Rantac) During Chemotherapy
- Allopurinol and Tumour Lysis Prevention
- Antibiotics and Antifungals During Chemotherapy
- Aprepitant (Aprecap, Emend) for Delayed Nausea
- Ayurvedic and Herbal Medicines Alongside Chemotherapy
- Cost of Supportive Medicines Across a Course
- Dexamethasone (Dexona) During Chemotherapy
- Emeset and Ondansetron for Chemotherapy Nausea
- Erythropoietin Injections for Low Haemoglobin
- Filgrastim (Grafeel, Neukine) Injections for Low Counts
- Leucovorin: Rescue and Modulation
- Long-Acting Growth Factor (Peg-Grafeel, Neulastim)
- Loperamide (Eldoper) for Chemotherapy Diarrhoea
- Mesna: Protecting the Bladder
- Mouthwashes and Mouth Care Medicines
- Painkillers That Are Safe During Chemotherapy
- Palonosetron and Longer-Acting Anti-Emetics
- The Medicines You Go Home With After Chemotherapy
- Vitamins and Supplements During Chemotherapy
- Why You Must Not Take Paracetamol Before Checking Your Temperature
Frequently asked questions
Does a different brand mean a different treatment?
No. A CDSCO-approved generic contains the same active molecule at the same dose as the originator brand. Indian drug regulation requires this as a condition of approval — no approved generic can legally differ in the active ingredient. The clinical effect of a treatment is determined by the molecule and its dose, not by the manufacturer's name on the vial. When you compare brands of the same molecule, you are asking about manufacturing source, not about the treatment itself.
Can I ask the hospital to switch to a cheaper generic?
Yes, and it is a reasonable question to put to your oncologist. The practical answer depends on whether a CDSCO-approved generic for your molecule is available and whether the hospital's pharmacy can source it within its procurement process. Not every hospital can accommodate every request, but many will engage with the conversation — particularly for long treatment courses where the cost difference across multiple cycles is significant. Raise it early, before treatment begins if possible.
Can I buy chemotherapy from a medical shop and bring it to the hospital?
In almost all cases, no. Chemotherapy is not dispensed from a retail pharmacy and self-administered — it requires specialist preparation under controlled, sterile conditions by trained pharmacy staff, often as an infusion calculated to your specific dose. Hospitals carry direct regulatory responsibility for any product they administer. Most will not accept medicine sourced externally. If cost is the concern behind this question, the right route is a conversation with your oncologist about sourcing options through the hospital itself.
Why is the price difference between originator brands and generics sometimes very large?
The originator brand carries the full cost of developing the molecule — years of research, clinical trials, and regulatory submissions across multiple countries, recovered through patent-protected pricing. A generic manufacturer enters at a later point, once the patent has expired or a licence is granted, and produces the same molecule without those development costs. That difference in cost structure is what makes generics substantially cheaper. The active molecule and its regulatory requirements are the same; the investment history behind the manufacturer is not.
What is a biosimilar, and is it the same as a generic?
Not exactly. A generic refers to a small chemical molecule that can be identically reproduced. A biosimilar applies to biological medicines — large, complex molecules made by living cells, such as monoclonal antibodies. These cannot be identically copied because the manufacturing process itself shapes the molecule. CDSCO requires a more rigorous comparability assessment for biosimilars than for small-molecule generics. An approved biosimilar has demonstrated no clinically meaningful difference from the reference product. Both terms describe approved alternatives to originator products, but the science and the regulatory pathway differ.
My insurance is paying for treatment. Does the brand still matter?
It can. Some insurance policies set sub-limits on specific therapies that may not cover the full cost of an originator brand, leaving you with a balance to pay. Others cover whatever the treating hospital prescribes. Before your first cycle, ask the hospital's billing team what they will submit to your insurer and whether any sub-limits apply. If a generic is available and cheaper, raising it with your oncologist is worthwhile even with coverage — it may reduce any gap you carry or preserve your policy limit for later in treatment.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Chemotherapy Topics
Browse our complete chemotherapy guide — 1133 pages on side effects, medicines, cost, daily life and care in Hyderabad. Tap any topic to read more.